Haemonetics Corporation (HAE)

NYSE: HAE · USD

$118

-1.84 (-1.5%)· Recorded snapshot

Market cap	5.4B
Revenue (ttm)	1.4B
Net income (ttm)	96.3M
EPS (ttm)	$2.06
Shares out	45.5M
P/E (trailing)	57.4x
P/E (forward)	21.6x
Volume	364,552
Beta	0.61

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 1.4B
Net income (ttm): 96.3M
EPS (ttm): $2.06
P/E (trailing): 57.4x
P/E (forward): 21.6x
Market cap: 5.4B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	ถือ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E21.6

P25 n/aP50 n/aP75 n/a

Trailing P/E57.4

P25 n/aP50 n/aP75 n/a

ROE11.2

P25 n/aP50 n/aP75 n/a

ROIC10.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All HAE indicators

Market & fundamental data

Available fields

274

Groups with data

Currency

USD

Showing 274 of 274 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000313143
Company name	Haemonetics Corporation
Country	United States
Country code	US
CUSIP number	405024100
Earnings date	2026-11-05
Earnings time	bmo
Employees	3,009
Employees change	-14
Employees growth	-0.46%
Enterprise value	$6.3B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-27
First seen	2026-05-09
Fiscal year end	March
Founded	1971
In index	RUSSELL2000
Industry	Medical Devices
IPO date	1991-05-09
Is primary listing	Yes
Is SPAC	No
ISIN number	US4050241003
Last 10-K release date	2026-05-20
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split date	2012-12-03
Last stock split type	Forward
Market cap	$5.4B
Market cap category	Mid-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$118.14
Price currency	USD
Sector	Healthcare
SIC code	3841
Stock price date	2026-10-28
Symbol	HAE
U.S. state	Massachusetts
Website	https://www.haemonetics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	23.58x
Average P/E ratio (10Y)	91.7x
Average P/E ratio (3Y)	28.69x
Average P/E ratio (5Y)	43.08x
Earnings yield	1.74%
EV/Earnings	66.26x
EV/EBIT	25.04x
EV/EBITDA	17.78x
EV/FCF	21.91x
EV/Sales	4.72x
FCF / EV yield	4.56%
FCF yield	5.36%
Forward EV/Sales	4.44x
Forward P/E	21.57x
Forward P/S	3.78x
Graham number	29.20338
Graham upside	-75.53%
Industry forward P/E	19.81x
Industry P/E	39.5x
Lynch fair value	$17.19
Lynch upside	-85.6%
P/(FCF - SBC) ratio	21.1x
P/(OCF - SBC) ratio	18.45x
P/B ratio	6.52x
P/E ratio	57.38x
P/FCF ratio	18.65x
P/OCF ratio	16.55x
P/S ratio	4.02x
PEG ratio	2.02x
Price/EBITDA ratio	15.13x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	18.85%
EBITDA margin	26.54%
Effective tax rate	26.18%
FCF margin	21.54%
Gross margin	59.33%
Operating margin	18.85%
Pretax margin	9.65%
Profit margin	7.12%
Profit per employee	$32,000
Profitable quarters	1
Profitable years	9
Revenue per employee	$449,323
ROA	6.6%
ROA (5Y)	5.69%
ROCE	12.12%
ROE	11.2%
ROE (5Y)	12.93%
ROIC	10.42%
ROIC (5Y)	9.59%
SBC / revenue	2.5%
Tax / revenue	2.53%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-37.17%
EPS growth (Q)	2.86%
EPS growth 3Y	-8.2%
EPS growth 5Y	10.45%
EPS growth quarters	1
EPS growth years	0
FCF growth	53.95%
FCF growth (Q)	225.61%
FCF growth (QoQ)	-16.63%
FCF growth 3Y	17.89%
FCF growth 5Y	41.11%
Gross profit growth	1.76%
Gross profit growth (Q)	4.78%
Gross profit growth 3Y	7.36%
Gross profit growth 5Y	12.34%
Net income growth	-41.05%
Net income growth (Q)	-3%
Net income growth 3Y	-11%
Net income growth 5Y	8.35%
Net income growth years	0
OCF growth	44.85%
OCF growth (Q)	200.79%
OCF growth (QoQ)	-26.24%
OCF growth 10Y	8.64%
OCF growth 3Y	9.47%
OCF growth 5Y	28.05%
Operating income growth	2.56%
Operating income growth (Q)	5.7%
Operating income growth 3Y	10.25%
Operating income growth 5Y	21.71%
Revenue growth	0.44%
Revenue growth (Q)	5.6%
Revenue growth (QoQ)	-2.01%
Revenue growth 10Y	4.09%
Revenue growth 3Y	3.53%
Revenue growth 5Y	8.4%
Revenue growth quarters	2
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-36.9M
Depreciation and amortization	$104M
EBIT	$254.8M
EBITDA	$358.8M
EPS	$2.06
FCF per share	$6.40
Financing cash flow	$-227.5M
Free cash flow	$291.2M
Free cash flow minus SBC	$257.4M
Gross profit	$802.2M
Income taxes	$34.1M
Investing cash flow	$-168.8M
Net borrowing	$-56.3M
Net cash flow	$-69.5M
Net income	$96.3M
Operating cash flow minus SBC	$294.3M
Operating income	$254.8M
Revenue	$1.4B
Stock-based compensation	$33.8M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.58
Book value per share	$18.41
Debt / EBITDA	3.18
Debt / equity	1.4
Debt / FCF	4.03
Goodwill	$656.9M
Interest coverage	9.3
Long-term assets	$1.6B
Long-term liabilities	$1.3B
Net cash (debt)	$-949.6M
Net cash / market cap	-17.49%
Net debt / EBITDA	2.65
Net debt / equity	1.13
Net debt / FCF	3.26
Piotroski F-Score	7
Property, plant and equipment	$303.8M
Shareholders' equity	$837.1M
Tangible book value	$-254.3M
Tangible book value per share	$-5.59
Total assets	$2.4B
Total cash	$224.5M
Total debt	$1.2B
Total liabilities	$1.5B
WACC	6.55%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.56
Current assets	$810.8M
Current liabilities	$263.2M
Current ratio	3.08
Inventory turnover	1.65
Net working capital	$328M
Quick ratio	1.67
Working capital	$547.6M
Working capital turnover	2.91

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	6.48%
Dividend yield	0%
Shareholder yield	6.48%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	259.26%
10Y return CAGR	13.65%
10Y total return	259.26%
150-day SMA	$83.12
15Y price change	267.61%
15Y return CAGR	9.07%
15Y total return	267.61%
1D price change	-1.53%
1M price change	12.73%
1M total return	12.73%
1W price change	0.41%
1W total return	0.41%
1Y price change	131.79%
1Y return CAGR	131.93%
1Y total return	131.79%
20-day SMA	$115.41
200-day SMA	$78.21
20Y price change	396.65%
20Y return CAGR	8.34%
20Y total return	396.65%
3M price change	48.54%
3M total return	48.54%
3Y price change	40.39%
3Y return CAGR	11.97%
3Y total return	40.39%
50-day SMA	$109.53
50-day SMA vs 200-day SMA	50over200
52-week high	$123.77
52-week high date	2026-10-13
52-week low	$48.98
52-week low date	2025-10-29
5Y price change	73.26%
5Y return CAGR	11.62%
5Y total return	73.26%
6M price change	96.26%
6M total return	96.26%
All-time high	$142.11
All-time high date	2021-02-09
All-time low	$5.78
All-time low date	1991-05-10
Average true range (ATR)	$3.40
Average volume	726K
Beta (1Y)	-0.06
Beta (2Y)	0.43
Beta (5Y)	0.61
Change from 52-week high	-4.55%
Change from 52-week low	141.2%
Change from all-time high	-16.47%
Change from all-time low	1,953.28%
Change from open	-1.7%
Day's gap	0.18%
Dollar volume	$43.1M
High price	$120.54
Low price	$117.71
Monthly RSI	68.57
Open price	$120.18
Position in 52-week range	15.19%
Premarket change	-0.38%
Premarket close	$119.97
Premarket price	$119.51
Previous close	$119.97
Price vs 150-day SMA	42.81%
Price vs 20-day SMA	2.85%
Price vs 200-day SMA	51.76%
Price vs 50-day SMA	8.38%
Relative volume	0.5
RSI	62.14
Sharpe ratio	1.79
Sharpe ratio (3Y)	0.34
Sharpe ratio (5Y)	0.36
Sortino ratio	4.38
Sortino ratio (3Y)	0.68
Sortino ratio (5Y)	0.69
Volume	364.6K
Weekly RSI	76.89
YTD price change	48.1%
YTD total return	48.1%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	44.9M
Float percentage	98.66%
Shares change (QoQ)	-1.12%
Shares change (YoY)	-6.48%
Shares held by insiders	1.3%
Shares held by institutions	109.98%
Shares outstanding	45.5M
Short % of float	6.77%
Short % of shares	6.68%
Short ratio	5.2 days

Deeper analysis on HAE

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this HAE report

Is a complete HAE research report available?

No complete published report is available for Haemonetics Corporation (HAE) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Haemonetics Corporation (HAE)

Price

Financial snapshot

Fair-value bridge

Latest news · HAE

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All HAE indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on HAE

Frequently asked questions